Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Stitch Fix reported a quarterly loss of 5 cents per share which beat the analyst consensus estimate of a loss of 13 cents per ...

PRISM+ has announced some good deals for you to snap during the upcoming 12.12 sale period. Ranging from smart TVs to gaming ...

Oppenheimer slashed its price target on the stock to $20 from $80, but maintained the stock at Outperform. This comes after ...